AI Quick Summary

🔍 Meet the Residents Across Our SI Parks! 🔎🌟 Introducing Swiss Biotech @Tigen Pharma SA, resident at @Biopôle site of @Switzerland Innovation Park West EPFLOncology is historically a core therapeutic focus at Biopôle. The presence of the oncology department of @CHUV/@UNIL and of @Ludwig Cancer Research works like a magnet for life sciences companies looking for research collaborations.Tigen is at the forefront of cell therapies for cancer treatment. In the world of cancer immunotherapy, their work is vital, aiming to empower the immune system to seek and eliminate cancer cells. This approach encompasses a diverse range of strategies, from monoclonal antibodies and cancer vaccines to the promising realm of cell therapy.🗣️ @Emmanuel Savioz, CEO of Tigen, shared his vision for the future of cell therapy and the potential of collaborations between industry and academia to expedite the development of innovative treatments.🤝 One example of such collaboration is Tigen's partnership with @Ludwig Cancer Research and @CHUV on the neoantigen-specific T-cell program. It's a prime demonstration of academia and industry joining forces, pooling their expertise to advance cell therapies and bring hope to patients.📖 Dive into the full interview here: Link to Interview🚀 #SwitzerlandInnovation #WhySwitzerland #CellTherapy #Collaborations #CancerImmunotherapy

Post Metadata

• Author: Switzerland Innovation Digital
• Published Date: 7/29/2024 9:45:15 AM
• Modified Date: 9/24/2024 12:33:44 PM

Post Description

🔍 Meet the Residents Across Our SI Parks! 🔎

🌟 Introducing Swiss Biotech @Tigen Pharma SA, resident at @Biopôle site of @Switzerland Innovation Park West EPFL

Oncology is historically a core therapeutic focus at Biopôle. The presence of the oncology department of @CHUV/@UNIL and of @Ludwig Cancer Research works like a magnet for life sciences companies looking for research collaborations.

Tigen is at the forefront of cell therapies for cancer treatment. In the world of cancer immunotherapy, their work is vital, aiming to empower the immune system to seek and eliminate cancer cells. This approach encompasses a diverse range of strategies, from monoclonal antibodies and cancer vaccines to the promising realm of cell therapy.

🗣️ @Emmanuel Savioz, CEO of Tigen, shared his vision for the future of cell therapy and the potential of collaborations between industry and academia to expedite the development of innovative treatments.

🤝 One example of such collaboration is Tigen's partnership with @Ludwig Cancer Research and @CHUV on the neoantigen-specific T-cell program. It's a prime demonstration of academia and industry joining forces, pooling their expertise to advance cell therapies and bring hope to patients.

📖 Dive into the full interview here: Link to Interview

🚀 #SwitzerlandInnovation #WhySwitzerland #CellTherapy #Collaborations #CancerImmunotherapy